Literature DB >> 22922447

Analysis of the absence of the detrusor muscle in initial transurethral resected specimens and the presence of residual tumor tissue.

Jiefu Huang1, Jinggao Fu, Hailun Zhan, Keji Xie, Bolong Liu, Fei Yang, Yangbo Lu, Xiangfu Zhou.   

Abstract

OBJECTIVE: To investigate the relationship between surgeon's experience, tumor characteristics, absent detrusor muscle (DM) tissue in resected specimens, and residual tumor after an initial transurethral resection. PATIENTS AND METHODS: We conducted an analysis of 216 patients from two centers over a 3-year period. Patients with primary bladder tumors that were judged to have been completely resected were recruited. The data included tumor characteristics, surgeon category, and DM status. Logistic regression multivariate analyses were conducted.
RESULTS: Large tumors, lateral/dome/anterior wall tumors, and surgery performed by junior surgeons were independently associated with absent DM. Large tumors, dome/anterior wall tumors, T1 and absent DM were independently associated with residual disease. The absence and presence of the DM were associated with residual tumor rates of 51.8 and 20.9%, respectively (OR 15.537). Resection by senior surgeons was associated with the presence of DM and clean resection (OR 0.274 and 0.141, respectively).
CONCLUSIONS: Absent DM and residual tumor were more likely to occur in cases involving large tumors that were located in the lateral/dome/anterior wall, especially when the surgery was performed by a junior surgeon. Absent DM appears to be a surrogate marker for residual disease.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22922447     DOI: 10.1159/000341103

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  7 in total

Review 1.  Transurethral Resection of Bladder Tumors: Improving Quality Through New Techniques and Technologies.

Authors:  Daniel Zainfeld; Siamak Daneshmand
Journal:  Curr Urol Rep       Date:  2017-05       Impact factor: 3.092

2.  Surgeon has a major impact on long-term recurrence risk in patients with non-muscle invasive bladder cancer.

Authors:  Alexander Rolevich; Alexander Minich; Tatiana Nabebina; Sergey Polyakov; Sergey Krasny; Oleg Sukonko
Journal:  Cent European J Urol       Date:  2016-04-19

3.  Utility of Fluorescence In Situ Hybridization (FISH) to Sub-Classify Low-Grade Urothelial Carcinoma for Prognostication.

Authors:  Yi Chen; Bo Tao; Ya Peng; Weijiao Yang; Chuang Wang; Xuebao Xiang; Tianyu Zhang; Li Gao; Jiaoyu Yi; Xiangfu Zhou; Jiefu Huang
Journal:  Med Sci Monit       Date:  2017-06-28

4.  Differences in Pathologic Results of Repeat Transurethral Resection of Bladder Tumor (TURBT) according to Institution Performing the Initial TURBT: Comparative Analyses between Referred and Nonreferred Group.

Authors:  Hyeong Dong Yuk; Jung Kwon Kim; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim; Ja Hyeon Ku
Journal:  Biomed Res Int       Date:  2018-09-06       Impact factor: 3.411

Review 5.  Transurethral resection of bladder tumour (TURBT).

Authors:  Lawrence H C Kim; Manish I Patel
Journal:  Transl Androl Urol       Date:  2020-12

6.  Risk Stratification for the Rate and Location of Residual Bladder Tumor for the Decision of Re-Transurethral Resection of Bladder Tumor.

Authors:  Junjie Fan; Xing Zhang; Jinhai Fan; Lei Li; Dalin He; Kaijie Wu
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

7.  Prediction of the risk of surgical complications in patients undergoing monopolar transurethral resection of bladder tumour - a prospective multicentre observational study.

Authors:  Sławomir Poletajew; Wojciech Krajewski; Dominika Gajewska; Joanna Sondka-Migdalska; Michał Borowik; Paweł Buraczyński; Mateusz Dzięgała; Marcin Łykowski; Maciej Przudzik; Andrzej Tukiendorf; Rafał Woźniak; Krzysztof Bar; Zbigniew Jabłonowski; Marek Roslan; Marcin Słojewski; Romuald Zdrojowy; Piotr Radziszewski; Konrad Dziobek
Journal:  Arch Med Sci       Date:  2019-10-07       Impact factor: 3.318

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.